Scleral device manages OSD

July 3, 2013

The Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) device is a useful method of managing ocular surface disease (OSD) and optical imperfections, reveals a new study.

The Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) device is a useful method of managing ocular surface disease (OSD) and optical imperfections, reveals a new study.

A team managed by Dr Ryan Dimit, Alkek Eye Center, Baylor College of Medicine, Houston, Texas, USA, retrospectively reivewed the clinical outcomes of 51 charts of patients fitted unilaterally or bilaterally with the scleral device. The outcome measures included patient demographics, ocular diagnoses, associated systemic conditions, best corrected visual acuity (BCVA) before and after fitting, Visual Function Questionnaire scores (VFQ-25), and ocular surface disease index (OSDI) scores.

The most common reasons for wearing the PROSE device included relieving the symptoms of severe to moderate dry eye syndrome (DES), management of refractive problems and management of various anomalies (the "Other" group).

BCVA improved in wearers for those in with DES or refractive problems by 17 and 10 letters, respectively. However, BCVA did not improve for patients in the "Other" group.

There were no serious complications and the PROSE device is regarded as a useful management option for ophthalmic conditions such as moderate to severe DES and irregular corneal astigmatism.

The paper can be viewed in the Journal of the British Contact Lens Association.